Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

Global Bispecific Antibodies market size to surpass US$ 50 Billion By 2030 Says Kuick Research Delhi, March 17, 2025 (GLOBE ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene”) (Nasdaq: ADAG), a company ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...

The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...